Kidney (Renal Cell) Cancer

Patients With Early Kidney Cancer See Significant Benefits With Robotic Partial Nephrectomy

(Keck School of Medicine of USC) July 10, 2018 - For patients with early kidney cancer, removing part of the kidney instead of the whole kidney is often a preferred treatment because the procedure can effectively remove tumors while preserving kidney function.

read article

Only Immuno-Oncology Combination Therapy Approved by Health Canada as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma

(Markets Insider) July 9, 2018 - Bristol-Myers Squibb Canada Co. today announced that immuno-oncology (I-O) combination therapy OPDIVO (nivolumab) 3mg/kg plus YERVOY (ipilimumab) 1mg/kg for intravenous injections, was approved by Health Canada for the treatment of adult patients with intermediate/poor-risk advanced or metastatic renal cell carcinoma (RCC).

read article

Priority Changes for Novartis Spell the End for Aveo Pharma Alliance

(Xconomy Boston) July 3, 2018 — When Aveo Pharmaceuticals found itself floundering three years ago in the wake of the FDA’s rejection of its lead cancer drug, Novartis threw out a lifeline: a partnership on another Aveo drug that would finance its development. Now Novartis is pulling that support away.

read article

FDA to Release List of Surrogate Endpoints in Oncology

(Regulatory Focus) June 25, 2018 - Scott Gottlieb, FDA Commissioner, said Monday at the National Press Club in Washington, DC that his agency will release a list of surrogate endpoints used in cancer drug development soon.

read article

Real-World Economic Outcomes for Patients Treated for Advanced Renal Cell Carcinoma

(Journal of Clinical Pathways) June 22, 2018 - A new study compared all-cause health care costs and health resource utilization associated with first targeted therapies for advanced renal cell carcinoma.

read article

SillaJen Announces First Patient Enrolled in Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Cemiplimab

(Morningstar) June 20, 2018 - SillaJen, Inc. announced the first patient has been enrolled in REN026, the Phase 1b clinical trial of Pexa-Vec (pexastimogene devacirepvec) in combination with cemiplimab (REGN2810) for the treatment of renal cell cancer (RCC).

read article

Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy

(Morningstar) June 14, 2018 - Apexigen, Inc., and Yale Cancer Center today announced a clinical trial collaboration to evaluate Apexigen's APX005M in combination with cabiralizumab and Opdivo in patients with advanced solid tumors.

read article

Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930

(NASDAQ) June 12, 2018 - Surface Oncology today announced the initiation of a Phase I trial of SRF373, a fully human antibody targeting CD73. SRF373, also known as NZV930, is the second of Surface's immunotherapies to advance into the clinic this year.

read article

Arcus Biosciences Announces FDA Clearance of INDs for AB928 and AB122 and Initiation of Phase 1/1b Program to Evaluate AB928 Combinations

(Arcus Biosciences) June 11, 2018 - Clearance of the first IND for AB928 allows the Company to proceed with its planned Phase 1/1b trial to evaluate the safety, tolerability and preliminary efficacy of AB928 in combination with other agents, including AB122 (the Company’s anti-PD-1 antibody) and chemotherapy, in patients with breast and gynecologic malignancies.

read corporate press release

Peloton Therapeutics Initiates Phase 2 Trial of Oral HIF-2α Inhibitor PT2977 for Treatment of von Hippel-Lindau Disease-associated Kidney Cancer

(Morningstar) June 6, 2018 - Peloton Therapeutics, Inc., announced today dosing of the first patient in a Phase 2 trial evaluating the efficacy and safety of lead investigational oncology agent, PT2977, to treat von Hippel-Lindau (VHL) disease-associated kidney cancer.

read article

Eisai and Merck Announce Data at 2018 ASCO Annual Meeting from Investigational Studies of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) Combination Therapy in Four Different Tumor Types

(Merck) June 3, 2018 - First presentation of LENVIMA/KEYTRUDA data in patients with unresectable hepatocellular carcinoma (HCC), which aims to be the first systemic combination of a TKI and immunotherapy for these patients, as well as squamous cell carcinoma of the head and neck (SCCHN).

read corporate press release

Phase III Trial Finds Many People With Advanced Kidney Cancer Do Not Need Surgery

(2018 ASCO) June 3, 2018 - A randomized phase III clinical trial showed that many people with advanced kidney cancer can avoid surgery to remove the kidney (nephrectomy), without compromising survival.

read press release

Nektar And Bristol Hurtle Forward With Experimental Cancer Drug

(Forbes) June 2, 2018 - Nektar Pharmaceuticals and Bristol-Myers Squibb said results for their experimental cancer drug, NKTR-214, pushing forward into late-stage trials testing the medicine against melanoma, renal cell carcinoma, and urothelial cancer.

read article

A Controversial ASCO Presentation Underscores Risk Bristol, Nektar Carry With Experimental Cancer Drug

(STAT) June 3, 2018 - On Saturday night, the controversy around the experimental cancer immunotherapy drug NKTR-214 ratcheted higher following a new data presentation at the American Society of Clinical Oncology annual meeting.

read article

Merck’s KEYTRUDA® (pembrolizumab) Showed Overall Response Rate of Nearly 40 Percent as First-Line Therapy in Patients with Advanced Clear Cell Renal Cell Carcinoma (RCC) in Phase 2 KEYNOTE-427 Study

(Merck) June 3, 2018 - Merck, known as MSD outside the United States and Canada, today announced interim results from Cohort A of KEYNOTE-427, a Phase 2 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as first-line treatment for advanced clear cell renal cell carcinoma (RCC).

read corporate press release

Preliminary Data for NKTR-214 in Combination with Opdivo (nivolumab) for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at ASCO 2018

(BMS) June 2, 2018 - Data from the Phase 1 dose-escalation and early data from the Phase 2 dose expansion phase of the ongoing PIVOT study highlighted as an oral presentation.

read corporate press release

Next-Generation Therapies in Focus at Year's Top Cancer Meeting

(Bloomberg Quint) June 1, 2018 - As the year’s biggest cancer conference kicks off in Chicago, investors are focused on new treatments that may help patients who don’t respond to the first wave of immune-boosting drugs and cocktails designed to increase their effectiveness.

read article (free registration required)

Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimumab) Provided Significant and Sustained Health-Related Quality of Life Improvements in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma in CheckMate -214 Study

(BMS) June 1, 2018 - In Phase 3 CheckMate -214 trial, treatment with Opdivo plus low-dose Yervoy led to statistically significant differences in patient-reported outcomes from baseline versus sunitinib through two years of follow-up.

read corporate press release

Exelixis Announces Further Expansion to Clinical Research Protocol for Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Anti-PD-L1 Immunotherapy in Patients with Locally Advanced or Metastatic Solid Tumors

(Exelixis) June 1, 2018 - Exelixis, Inc. today announced an amendment to the protocol for COSMIC-021, the phase 1b trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with locally advanced or metastatic solid tumors to add 10 new expansion cohorts to the trial.

read corporate press release

Obesity Now Linked To 12 Different Cancers

(The Guardian [UK]) May 23, 2018 - Obesity is linked to as many as 12 different forms of cancer, according to a major new report which advises giving up bacon and swapping sugary drinks for water as part of a 10-point plan for avoiding the disease.

read article
Next Page